{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T06:22:08Z","timestamp":1785046928823,"version":"3.55.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Using data from the German Biologics JIA Registry (BIKER), long-term safety of biologics for systemic-onset JIA with regard to adverse events of special interest was assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Safety assessments were based on adverse event reports after first dose through 90\u2009days after last dose. Rates of adverse event, serious adverse event and 25 predefined adverse events of special interest were analysed. Incidence rates were compared for each biologic against all other biologics combined applying a mixed-effect Poisson model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 260 systemic-onset JIA patients in this analysis, 151 patients received etanercept, 109 tocilizumab, 71 anakinra and 51 canakinumab. Patients with etanercept had higher clinical Juvenile Arthritis Disease Activity Score 10 scores, active joint counts and steroid use at therapy start. Serious adverse events were reported with higher frequency in patients receiving canakinumab [20\/100\u2009patient years (PY)] and tocilizumab (21\/100\u2009PY). Cytopenia and hepatic events occurred with a higher frequency with tocilizumab and canakinumab. Medically important infections were seen more often in patients with IL-6 or IL-1 inhibition. Macrophage activation syndrome occurred in all cohorts with a higher frequency in patients with canakinumab (3.2\/100\u2009PY) and tocilizumab (2.5\/100\u2009PY) vs anakinra (0.83\/100\u2009PY) and etanercept (0.5\/100\u2009PY). After adjustment only an elevated risk for infections in anakinra-treated patients remained significant. Three definite malignancies were reported in patients ever exposed to biologics. Two deaths occurred in patients treated with etanercept.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Surveillance of pharmacotherapy as provided by BIKER is an import approach especially for patients on long-term treatment. Overall, tolerance was acceptable. Differences between several biologics were noted and should be considered in daily patient care.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/kez577","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T20:10:07Z","timestamp":1573589407000},"page":"2287-2298","source":"Crossref","is-referenced-by-count":37,"title":["Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry"],"prefix":"10.1093","volume":"59","author":[{"given":"Ariane","family":"Klein","sequence":"first","affiliation":[{"name":"Centre for Paediatric Rheumatology, Department of Paediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin"},{"name":"Department of Pediatrics, Medical Faculty, University of Cologne, Cologne"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Klotsche","sequence":"additional","affiliation":[{"name":"German Rheumatism Research Centre Berlin, and Charit\u00e9, University Medicine, Berlin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"H\u00fcgle","sequence":"additional","affiliation":[{"name":"German Centre Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Minden","sequence":"additional","affiliation":[{"name":"German Rheumatism Research Centre Berlin, and Charit\u00e9, University Medicine, Berlin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Hospach","sequence":"additional","affiliation":[{"name":"Pediatric Rheumatology, Olga Hospital, Stuttgart"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Weller-Heinemann","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Prof. Hess Children\u2019s Hospital, Bremen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology, St Josef Hospital, Sendenhorst"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Dressler","sequence":"additional","affiliation":[{"name":"Pediatric Pneumology, Allergology, Neonatology, Immunology, Medizinische Hochschule Hannover, Hannover"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Trauzeddel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Helios Klinik, Berlin-Buch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hufnagel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine, University Medical Center, Freiburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Foeldvari","sequence":"additional","affiliation":[{"name":"Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Borte","sequence":"additional","affiliation":[{"name":"Pediatric Immunology, Children\u2019s Hospital Sankt Georg, Leipzig"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Kuemmerle-Deschner","sequence":"additional","affiliation":[{"name":"Pediatric Rheumatology, University Childre\u0144s Hospital, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Brunner","sequence":"additional","affiliation":[{"name":"Department of Pediatrics I, Medical University, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad Thomas","family":"Oommen","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, University Children\u2019s Hospital, Heinrich-Heine-University, D\u00fcsseldorf"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"F\u00f6ll","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Rheumatology and Immunology, University Hospital, M\u00fcnster"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Tenbrock","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescent Medicine, RWTH Aachen University, Aachen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Urban","sequence":"additional","affiliation":[{"name":"Klinikum St Marien Klinik f\u00fcr Kinder und Jugendliche \u2013 Rheumatology\/Pneumology, Amberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Horneff","sequence":"additional","affiliation":[{"name":"Centre for Paediatric Rheumatology, Department of Paediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin"},{"name":"Department of Pediatrics, Medical Faculty, University of Cologne, Cologne"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"key":"2020082700371475100_kez577-B1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0950-3579(98)80018-6","article-title":"Systemic onset juvenile rheumatoid arthritis","volume":"12","author":"Schneider","year":"1998","journal-title":"Baillieres Clin Rheumatol"},{"key":"2020082700371475100_kez577-B2","first-page":"491","article-title":"Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years","volume":"27","author":"Lomater","year":"2000","journal-title":"J Rheumatol"},{"key":"2020082700371475100_kez577-B3","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade","volume":"201","author":"Pascual","year":"2005","journal-title":"J Exp Med"},{"key":"2020082700371475100_kez577-B4","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/art.1780340912","article-title":"Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis","volume":"34","author":"De Benedetti","year":"1991","journal-title":"Arthritis Rheum"},{"key":"2020082700371475100_kez577-B5","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2020082700371475100_kez577-B6","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"2020082700371475100_kez577-B7","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"2020082700371475100_kez577-B8","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"2020082700371475100_kez577-B9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/rheumatology\/kem271","article-title":"New insights in systemic juvenile idiopathic arthritis\u2014from pathophysiology to treatment","volume":"47","author":"Frosch","year":"2007","journal-title":"Rheumatology"},{"key":"2020082700371475100_kez577-B10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/adc.85.5.421","article-title":"Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders","volume":"85","author":"Sawhney","year":"2001","journal-title":"Arch Dis Child"},{"key":"2020082700371475100_kez577-B11","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1136\/ard.2003.014886","article-title":"The German etanercept registry for treatment of juvenile idiopathic arthritis","volume":"63","author":"Horneff","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"2020082700371475100_kez577-B12","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.2011.1671","article-title":"Factors associated with treatment response to etanercept in juvenile idiopathic arthritis","volume":"306","author":"Otten","year":"2011","journal-title":"JAMA"},{"key":"2020082700371475100_kez577-B13","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/art.10885","article-title":"Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type","volume":"48","author":"Quartier","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2020082700371475100_kez577-B14","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study","volume":"66","author":"Vastert","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2020082700371475100_kez577-B15","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/art.40865","article-title":"Treat-to-target using first-line recombinant interleukin-1 receptor antagonist monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five year follow-up study","volume":"71","author":"ter Haar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2020082700371475100_kez577-B16","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.38092","article-title":"2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications","volume":"65","author":"Ringold","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2020082700371475100_kez577-B17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12969-017-0157-1","article-title":"Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans","volume":"15","author":"Kimura","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"2020082700371475100_kez577-B18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/ard.2007.087593","article-title":"Safety and effectiveness of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry","volume":"68","author":"Horneff","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2020082700371475100_kez577-B19","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/rheumatology\/kes019","article-title":"Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO","volume":"51","author":"Minden","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2020082700371475100_kez577-B20","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2020082700371475100_kez577-B21"},{"key":"2020082700371475100_kez577-B22","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/rheumatology\/keq361","article-title":"Report on malignancies in the German juvenile idiopathic arthritis registry","volume":"50","author":"Horneff","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"2020082700371475100_kez577-B23","first-page":"1113","article-title":"Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry","volume":"34","author":"Horneff","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2020082700371475100_kez577-B24","doi-asserted-by":"crossref","first-page":"285.","DOI":"10.1186\/s13075-018-1780-z","article-title":"Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries","volume":"20","author":"Swart","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2020082700371475100_kez577-B25","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1002\/art.39197","article-title":"Medically significant infections are increased in patients with juvenile idiopathic arthritis treated with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology etanercept cohort study","volume":"67","author":"Davies","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2020082700371475100_kez577-B26","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/art.24777","article-title":"Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis","volume":"60","author":"Giannini","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2020082700371475100_kez577-B27","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1136\/annrheumdis-2015-207818","article-title":"Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan","volume":"75","author":"Yokota","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2020082700371475100_kez577-B28","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3899\/jrheum.180795","article-title":"Neutropenia during tocilizumab treatment is not associated with infection risk in systemic or polyarticular-course juvenile idiopathic arthritis","volume":"46","author":"Pardeo","year":"2019","journal-title":"J Rheumatol"},{"key":"2020082700371475100_kez577-B29","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/ard.2007.087411","article-title":"Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register","volume":"68","author":"Prince","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2020082700371475100_kez577-B30","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1002\/art.34458","article-title":"Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment","volume":"64","author":"Beukelman","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2020082700371475100_kez577-B31","doi-asserted-by":"crossref","first-page":"1025.","DOI":"10.1007\/s10067-018-4367-9","article-title":"The frequency of infections in patients with juvenile idiopathic arthritis on biologic agents: 1-year prospective study","volume":"38","author":"Aygun","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2020082700371475100_kez577-B32","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/14397595.2017.1349059","article-title":"High rate of serious infection in juvenile idiopathic arthritis patients under biologic therapy in a real-life setting","volume":"28","author":"Brunelli","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2020082700371475100_kez577-B33","doi-asserted-by":"crossref","first-page":"210.","DOI":"10.1186\/s13075-016-1109-8","article-title":"The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis","volume":"18","author":"Beukelman","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2020082700371475100_kez577-B34","first-page":"1133","article-title":"Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis","volume":"34","author":"Behrens","year":"2007","journal-title":"J Rheumatol"},{"key":"2020082700371475100_kez577-B35","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/art.39407","article-title":"Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab","volume":"68","author":"Grom","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2020082700371475100_kez577-B36","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","article-title":"Macrophage activation syndrome in the era of biologic therapy","volume":"12","author":"Grom","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2020082700371475100_kez577-B37","first-page":"401","article-title":"Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis","volume":"30","author":"Ramanan","year":"2003","journal-title":"J Rheumatol"},{"key":"2020082700371475100_kez577-B38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000338179","article-title":"Critical imbalance of TNF-\u03b1 and soluble TNF receptor 1 in a patient with macrophage activation syndrome: potential implications for diagnostics and treatment","volume":"128","author":"Flammiger","year":"2012","journal-title":"Acta Haematol"},{"key":"2020082700371475100_kez577-B39","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/acr.22487","article-title":"Novel method to collect medication adverse events in juvenile arthritis: results from the childhood arthritis and rheumatology research alliance enhanced drug safety surveillance project","volume":"67","author":"Ringold","year":"2015","journal-title":"Arthritis Care Res"},{"key":"2020082700371475100_kez577-B40","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.34348","article-title":"Rates of malignancy associated with juvenile idiopathic arthritis and its treatment","volume":"64","author":"Beukelman","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2020082700371475100_kez577-B41","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/rheumatology\/key088","article-title":"Depressive symptoms, pain and disability for adolescent patients with juvenile idiopathic arthritis: results from the Childhood Arthritis Prospective Study","volume":"57","author":"Hanns","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2020082700371475100_kez577-B42","first-page":"343","article-title":"Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR)","volume":"35","author":"Behrens","year":"2008","journal-title":"J Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/9\/2287\/33686397\/kez577.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/9\/2287\/33686397\/kez577.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T04:37:35Z","timestamp":1598503055000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/59\/9\/2287\/5679818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,17]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,12,17]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kez577","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2019,12,17]]}}}